BibTex RIS Cite

Paclitaxel-Carboplatin based therapy in elderly patients with Non-small Cell Lung Cancer

Year 2017, Volume: 3 Issue: 2, 101 - 104, 22.06.2017

Özlem Özkul Hasan Morcalı Bayram Kızılkaya Gökhan Puşuroğlu Yasemin Bakkal Temi Cemil Bilir

Abstract

Background:
Nonsmall cell lung cancer (NSCLC) is increasingly seen in the elderly
population. At the time of diagnosis, more than half of the patients are over
65 years of age.

Method: We
retrospectively analyzed our hospital records. NSCLC patients treated with
combination either chemotherapy or combination with radiation according to the
stage.

Results: The median follow up period was 20 months and 9 (32%)
patients died during this period. Patients with stage IV patients had 7.9
months median OS, patients who had locally advanced stage had 19 months median
OS. Serum uric acid levels were significantly correlated with overall survival
and overall response rates in locally advanced disease (HR 1.01-2.4, P=0.05 and
0.02, respectively).







Conclusion: Our
results showed that combination therapy with taxanes and platinums can be
effective choice for selected elderly patients and we can use serum uric acid
levels as a prognostic factor who had advanced NSCLC.

Keywords

elderly patients uric acid

References

  • 1- Owoniko TK,Ragin CC,Belani CP, et al.Lung cancer in elderly patients :an analysis of the surveillance ,epidemiology,and end results database .J Clin Oncol 2007;25:5570-5577.
  • 2- Repetto L,Luciani A. Cancer treatment in elderly patients :evidence and clinical research.Recenti Prog Med 2015;106:23-7.
  • 3- Ries LAG,Eisner MP,Kosary CL,et al: SEER Cancer Statistics Review 1975-2000
  • 4- Perrone F,Gallo C,Gridelli C:Re:Cisplatin-based therapy for elderly patients with advanced non – small cell lung cancer:Implications of Eastern Cooperative Oncology gRoup 5592,a randomized trial.J Natl Cancer INST 94:1029-1031,2002.
  • 5- Jatoi A,Hillman S,Stella P,et al:Should elderly non-small cell lung cancer patients be offered elderly-specific trials?Results of a pooled analysis from the North Central Cancer Treatment Group.J Clin Oncol 23:9113-9119,2005.
  • 6- Sieger R.,M J,Zou Z,Jemal A.Cancer statistics ,2014.CA Cancer J Clin 2014;64:9-29.
  • 7- Berghmans T,Paersmans M,Sculier JP.Prognostic factors in stage 3 non-small cell lung cancer :a review on conventional,metabolic and new biological variables.Ther Adv Med Oncol 2011;3:127-38.
  • 8- Jemal A,Siegel R,Ward E,Murray T,Xu J,Thun MJ.Cancer statistics ,2007.CA Cancer J Clin 2007;57:43-66. 9- Edwards BK,Howe HL,Ries LA,et al.Annual report to the nation on the status of cancer ,1973-1999,featuring implications of age and aging on U.S cancer burden.Cancer .2002;94:2766-2792.
  • 10- Fentiman IS,Tirelli U,Monfardini S,et al.Cancer in the elderly :why so badly treated ? Lancet. 1990;335:1020-1022.
  • 11- Langer C, Hsu C, Curran WJ, et al. Elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy: Secondary analysis of Radiation Therapy Oncology Group (RTOG) 94-10. Proc Am Soc Clin Oncol 2002;21.
  • 12- Atagi S,Kawahara M,Tamura T,et al:Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer :A phase 3 trial of the Japan Clinical Oncology Group (JCOG9812).Jpn J Clin Oncol 35:195-201,2005
  • 13- Gridelli C, Balducci L, Ciardello F, et al. Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer 2015; 16(5):325-33.
  • 14- Hainsworth JD, Spigel DR, Farley C, et al. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer. 2007;110:2027–2034.
  • 15- Seung Tae Kim,MD,PhD,Kyong Hwa Park ,MD,PhD,Sang CheulOh,MD,PhD et al.Chemotherapy in Patients Older Than or Equal to 75 Years with Advanced Non-Small Cell Lung Cancer :Cancer Res Treat 2012;44(1):37-42.
  • 16- Ö.Tanrıverdi,S.Cokmert,E.Oktay et al.Prognostic significance of the baseline serum uric acid level in non-small cell lung cancer patients treated with first-line chemotherapy :a study of the Turkish Descriptive Oncological Researches Group.Med Oncol (2014)31:217

Year 2017, Volume: 3 Issue: 2, 101 - 104, 22.06.2017

Özlem Özkul Hasan Morcalı Bayram Kızılkaya Gökhan Puşuroğlu Yasemin Bakkal Temi Cemil Bilir

Abstract

References

  • 1- Owoniko TK,Ragin CC,Belani CP, et al.Lung cancer in elderly patients :an analysis of the surveillance ,epidemiology,and end results database .J Clin Oncol 2007;25:5570-5577.
  • 2- Repetto L,Luciani A. Cancer treatment in elderly patients :evidence and clinical research.Recenti Prog Med 2015;106:23-7.
  • 3- Ries LAG,Eisner MP,Kosary CL,et al: SEER Cancer Statistics Review 1975-2000
  • 4- Perrone F,Gallo C,Gridelli C:Re:Cisplatin-based therapy for elderly patients with advanced non – small cell lung cancer:Implications of Eastern Cooperative Oncology gRoup 5592,a randomized trial.J Natl Cancer INST 94:1029-1031,2002.
  • 5- Jatoi A,Hillman S,Stella P,et al:Should elderly non-small cell lung cancer patients be offered elderly-specific trials?Results of a pooled analysis from the North Central Cancer Treatment Group.J Clin Oncol 23:9113-9119,2005.
  • 6- Sieger R.,M J,Zou Z,Jemal A.Cancer statistics ,2014.CA Cancer J Clin 2014;64:9-29.
  • 7- Berghmans T,Paersmans M,Sculier JP.Prognostic factors in stage 3 non-small cell lung cancer :a review on conventional,metabolic and new biological variables.Ther Adv Med Oncol 2011;3:127-38.
  • 8- Jemal A,Siegel R,Ward E,Murray T,Xu J,Thun MJ.Cancer statistics ,2007.CA Cancer J Clin 2007;57:43-66. 9- Edwards BK,Howe HL,Ries LA,et al.Annual report to the nation on the status of cancer ,1973-1999,featuring implications of age and aging on U.S cancer burden.Cancer .2002;94:2766-2792.
  • 10- Fentiman IS,Tirelli U,Monfardini S,et al.Cancer in the elderly :why so badly treated ? Lancet. 1990;335:1020-1022.
  • 11- Langer C, Hsu C, Curran WJ, et al. Elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy: Secondary analysis of Radiation Therapy Oncology Group (RTOG) 94-10. Proc Am Soc Clin Oncol 2002;21.
  • 12- Atagi S,Kawahara M,Tamura T,et al:Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer :A phase 3 trial of the Japan Clinical Oncology Group (JCOG9812).Jpn J Clin Oncol 35:195-201,2005
  • 13- Gridelli C, Balducci L, Ciardello F, et al. Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer 2015; 16(5):325-33.
  • 14- Hainsworth JD, Spigel DR, Farley C, et al. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer. 2007;110:2027–2034.
  • 15- Seung Tae Kim,MD,PhD,Kyong Hwa Park ,MD,PhD,Sang CheulOh,MD,PhD et al.Chemotherapy in Patients Older Than or Equal to 75 Years with Advanced Non-Small Cell Lung Cancer :Cancer Res Treat 2012;44(1):37-42.
  • 16- Ö.Tanrıverdi,S.Cokmert,E.Oktay et al.Prognostic significance of the baseline serum uric acid level in non-small cell lung cancer patients treated with first-line chemotherapy :a study of the Turkish Descriptive Oncological Researches Group.Med Oncol (2014)31:217
There are 15 citations in total.

Details

Subjects Health Care Administration
Journal Section Articles
Authors

Özlem Özkul

Hasan Morcalı This is me

Bayram Kızılkaya This is me

Gökhan Puşuroğlu This is me

Yasemin Bakkal Temi This is me

Cemil Bilir This is me

Publication Date June 22, 2017
Submission Date June 22, 2017
Acceptance Date June 13, 2017
Published in Issue Year 2017 Volume: 3 Issue: 2

Cite

APA Özkul, Ö., Morcalı, H., Kızılkaya, B., Puşuroğlu, G., et al. (2017). Paclitaxel-Carboplatin based therapy in elderly patients with Non-small Cell Lung Cancer. Journal of Human Rhythm, 3(2), 101-104.
AMA Özkul Ö, Morcalı H, Kızılkaya B, Puşuroğlu G, Temi YB, Bilir C. Paclitaxel-Carboplatin based therapy in elderly patients with Non-small Cell Lung Cancer. Journal of Human Rhythm. June 2017;3(2):101-104.
Chicago Özkul, Özlem, Hasan Morcalı, Bayram Kızılkaya, Gökhan Puşuroğlu, Yasemin Bakkal Temi, and Cemil Bilir. “Paclitaxel-Carboplatin Based Therapy in Elderly Patients With Non-Small Cell Lung Cancer”. Journal of Human Rhythm 3, no. 2 (June 2017): 101-4.
EndNote Özkul Ö, Morcalı H, Kızılkaya B, Puşuroğlu G, Temi YB, Bilir C (June 1, 2017) Paclitaxel-Carboplatin based therapy in elderly patients with Non-small Cell Lung Cancer. Journal of Human Rhythm 3 2 101–104.
IEEE Ö. Özkul, H. Morcalı, B. Kızılkaya, G. Puşuroğlu, Y. B. Temi, and C. Bilir, “Paclitaxel-Carboplatin based therapy in elderly patients with Non-small Cell Lung Cancer”, Journal of Human Rhythm, vol. 3, no. 2, pp. 101–104, 2017.
ISNAD Özkul, Özlem et al. “Paclitaxel-Carboplatin Based Therapy in Elderly Patients With Non-Small Cell Lung Cancer”. Journal of Human Rhythm 3/2 (June 2017), 101-104.
JAMA Özkul Ö, Morcalı H, Kızılkaya B, Puşuroğlu G, Temi YB, Bilir C. Paclitaxel-Carboplatin based therapy in elderly patients with Non-small Cell Lung Cancer. Journal of Human Rhythm. 2017;3:101–104.
MLA Özkul, Özlem et al. “Paclitaxel-Carboplatin Based Therapy in Elderly Patients With Non-Small Cell Lung Cancer”. Journal of Human Rhythm, vol. 3, no. 2, 2017, pp. 101-4.
Vancouver Özkul Ö, Morcalı H, Kızılkaya B, Puşuroğlu G, Temi YB, Bilir C. Paclitaxel-Carboplatin based therapy in elderly patients with Non-small Cell Lung Cancer. Journal of Human Rhythm. 2017;3(2):101-4.